Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Katayama

Showing results (111-120 of 149) with videos related to

Pageof 15
Sort By:
The Journal of Urology|June 28, 2021
Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical CystectomyVictor M Schuettfort, Benjamin Pradere, David D'Andrea, et al.
The Prostate|May 31, 2021
The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancerFahad Quhal, Pawel Rajwa, Keiichiro Mori, et al.
Urologic Oncology|June 12, 2021
Impact of systemic Immune-inflammation Index on oncologic outcomes in patients treated with radical prostatectomy for clinically nonmetastatic prostate cancerPawel Rajwa, Victor M Schuettfort, David D'Andrea, et al.
Cancer Immunology, Immunotherapy : CII|February 25, 2026
A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortiumTakafumi Yanagisawa, Keiichiro Mori, Tatsushi Kawada, et al.
Minerva Urology and Nephrology|July 26, 2021
Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profileKeiichiro Mori, Fahad Quhal, Satoshi Katayama, et al.
Clinical Genitourinary Cancer|February 7, 2022
Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter StudyNico C Grossmann, Benjamin Pradere, David D'Andrea, et al.
Japanese Journal of Clinical Oncology|August 23, 2024
Clinical outcomes and prognostic factors in metastatic nonclear cell renal cell carcinoma treated with immuno-oncology combination therapyShingo Toyoda, Wataru Fukuokaya, Keiichiro Mori, et al.
International Journal of Clinical Oncology|September 5, 2025
Predictors of early progressive disease and antitumor effects by metastatic site in renal cell carcinoma treated with ipilimumab plus nivolumabKeiichiro Mori, Takafumi Yanagisawa, Tatsushi Kawada, et al.
Clinical Genitourinary Cancer|November 12, 2021
Discordance Between Clinical and Pathological Staging and Grading in Upper Tract Urothelial CarcinomaKeiichiro Mori, Satoshi Katayama, Ekaterina Laukhtina, et al.
Clinical Genitourinary Cancer|May 19, 2024
Effect of Antacids on the Survival of Patients With Metastatic Urothelial Carcinoma Treated With PembrolizumabTakanori Sekito, Kensuke Bekku, Satoshi Katayama, et al.
Pageof 15

Showing results (111-120 of 149) with videos related to

Sort By:
Pageof 15
The Journal of Urology|June 28, 2021
Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical CystectomyVictor M Schuettfort, Benjamin Pradere, David D'Andrea, et al.
The Prostate|May 31, 2021
The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancerFahad Quhal, Pawel Rajwa, Keiichiro Mori, et al.
Urologic Oncology|June 12, 2021
Impact of systemic Immune-inflammation Index on oncologic outcomes in patients treated with radical prostatectomy for clinically nonmetastatic prostate cancerPawel Rajwa, Victor M Schuettfort, David D'Andrea, et al.
Cancer Immunology, Immunotherapy : CII|February 25, 2026
A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortiumTakafumi Yanagisawa, Keiichiro Mori, Tatsushi Kawada, et al.
Minerva Urology and Nephrology|July 26, 2021
Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profileKeiichiro Mori, Fahad Quhal, Satoshi Katayama, et al.
Clinical Genitourinary Cancer|February 7, 2022
Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter StudyNico C Grossmann, Benjamin Pradere, David D'Andrea, et al.
Japanese Journal of Clinical Oncology|August 23, 2024
Clinical outcomes and prognostic factors in metastatic nonclear cell renal cell carcinoma treated with immuno-oncology combination therapyShingo Toyoda, Wataru Fukuokaya, Keiichiro Mori, et al.
International Journal of Clinical Oncology|September 5, 2025
Predictors of early progressive disease and antitumor effects by metastatic site in renal cell carcinoma treated with ipilimumab plus nivolumabKeiichiro Mori, Takafumi Yanagisawa, Tatsushi Kawada, et al.
Clinical Genitourinary Cancer|November 12, 2021
Discordance Between Clinical and Pathological Staging and Grading in Upper Tract Urothelial CarcinomaKeiichiro Mori, Satoshi Katayama, Ekaterina Laukhtina, et al.
Clinical Genitourinary Cancer|May 19, 2024
Effect of Antacids on the Survival of Patients With Metastatic Urothelial Carcinoma Treated With PembrolizumabTakanori Sekito, Kensuke Bekku, Satoshi Katayama, et al.
Pageof 15